Informed Momentum Co LLC bought a new stake in Benitec Biopharma Limited (NASDAQ:BNTC - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 39,330 shares of the biotechnology company's stock, valued at approximately $512,000. Informed Momentum Co LLC owned 0.17% of Benitec Biopharma at the end of the most recent quarter.
A number of other hedge funds have also made changes to their positions in BNTC. Ameriprise Financial Inc. grew its holdings in Benitec Biopharma by 138.4% during the 4th quarter. Ameriprise Financial Inc. now owns 35,476 shares of the biotechnology company's stock valued at $448,000 after purchasing an additional 20,597 shares in the last quarter. 683 Capital Management LLC acquired a new stake in Benitec Biopharma during the 4th quarter valued at $452,000. Northern Trust Corp grew its holdings in Benitec Biopharma by 54.2% during the 4th quarter. Northern Trust Corp now owns 38,200 shares of the biotechnology company's stock valued at $482,000 after purchasing an additional 13,425 shares in the last quarter. MYDA Advisors LLC acquired a new stake in Benitec Biopharma during the 4th quarter valued at $632,000. Finally, Lion Point Capital LP grew its holdings in Benitec Biopharma by 59.0% during the 4th quarter. Lion Point Capital LP now owns 62,000 shares of the biotechnology company's stock valued at $783,000 after purchasing an additional 23,000 shares in the last quarter. Hedge funds and other institutional investors own 52.19% of the company's stock.
Benitec Biopharma Stock Up 2.8%
BNTC stock traded up $0.35 during mid-day trading on Friday, hitting $13.01. 58,291 shares of the company were exchanged, compared to its average volume of 53,404. The company has a market capitalization of $341.51 million, a PE ratio of -8.62 and a beta of 0.40. The company has a current ratio of 14.80, a quick ratio of 14.80 and a debt-to-equity ratio of 0.01. Benitec Biopharma Limited has a twelve month low of $8.06 and a twelve month high of $17.15. The firm has a fifty day simple moving average of $12.93 and a 200 day simple moving average of $13.08.
Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.36) by $0.12. On average, research analysts forecast that Benitec Biopharma Limited will post -1.48 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of equities research analysts recently weighed in on BNTC shares. JMP Securities reaffirmed a "market outperform" rating and set a $20.00 price target on shares of Benitec Biopharma in a report on Thursday, May 15th. HC Wainwright reaffirmed a "buy" rating and set a $28.00 price target on shares of Benitec Biopharma in a report on Monday, May 19th. Finally, TD Cowen started coverage on shares of Benitec Biopharma in a report on Monday, July 7th. They set a "buy" rating for the company. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $26.00.
Get Our Latest Stock Analysis on Benitec Biopharma
About Benitec Biopharma
(
Free Report)
Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
Featured Articles
Before you consider Benitec Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Benitec Biopharma wasn't on the list.
While Benitec Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access